Global News

Imprimis acquires intellectual property for drug candidate

Friday, July 26, 2013 03:11 PM

Imprimis Pharmaceuticals, which focuses on the commercialization of drug formulations utilizing the FDA drug development pathway, has acquired intellectual property for IPI-120, a novel drug formulation of both tranexamic acid, a synthetic derivative of the amino acid lysine, and an antibiotic. The company's recently-filed patent application combines tranexamic acid with an antibiotic to provide the clotting effects along with protection or treatment against infection in a transdermal, local intra-wound application or intra-cavity instillation formulation.

More... »

Aptuit names Maurizio Denaro general manager

Friday, July 26, 2013 03:10 PM

Global pharmaceutical company Aptuit has appointed Dr. Maurizio Denaro general manager of The Aptuit Center for Discovery & Development in Verona, Italy.

More... »

Charleston Laboratories completes pre-IND meeting

Friday, July 26, 2013 03:10 PM

Charleston Laboratories, a specialty pharmaceutical company focused on the R&D of novel pain products, has announced the completion of its scheduled pre-IND meeting with the FDA for CL-H1T, a novel treatment for patients who have migraine pain and migraine induced nausea or vomiting.

More... »

Cytokinetics provides update, revised guidance for BENEFIT-ALS

Friday, July 26, 2013 03:08 PM

Biopharmaceutical company Cytokinetics has amended the protocol for Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in amyotrophic lateral sclerosis (BENEFIT-ALS). BENEFIT-ALS is a phase IIb, multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv, a fast skeletal muscle troponin activator, in patients with ALS.

More... »

Chiltern names Andrew Monaghan director, global pharmacovigilance

Friday, July 26, 2013 03:07 PM

Global CRO Chiltern International has appointed Andrew Monaghan, Ph.D., director, global pharmacovigilance. Monaghan will lead the pharmacovigilance team and expand the company’s pharmacovigilance offering.

More... »

Recordati acquires Tunisian pharmaceutical Opalia Pharma

Friday, July 26, 2013 03:06 PM

International pharmaceutical group Recordati has acquired Opalia Pharma, a Tunisian pharmaceutical company. The transaction is valued at $48 million, paid in cash, and is subject to prior approval by Tunisian authorities. Opalia Pharma markets dermatology, gastrointestinal and respiratory therapeutic products in a cGMP certified facility specialized in liquid and semi-solid forms.

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

Icon reports second quarter 2013 revenue of $334 million

Friday, July 26, 2013 03:03 PM

CRO Icon said net revenues grew 21% to $334.2 million in the second quarter ended June 30, from $277 million in the year-ago quarter. Revenue in the first half of 2013 rose 23% to $651 million, from $529 million a year ago.

More... »

Iran's healthcare market growing

Friday, July 26, 2013 03:02 PM

Iran is ranked 15th among Middle East and Africa (MEA) countries in terms of long-term investment potential—its large youth population cohort, coupled with its healthcare reforms, promise growth in the private sector and investments in the pharmaceutical, healthcare facilities and medical devices markets, according to new research from Frost & Sullivan.

More... »

Teva, Lonza discontinue biosmilar venture

Friday, July 26, 2013 09:30 AM

Teva Pharmaceutical Industries of Jerusalem and Lonza Group, based in Switzerland, have decided to discontinue their joint venture for the development, manufacturing and marketing of biosimilars. The companies said ending the collaboration, which began in 2009, will enable both to better advance their own strategies and efforts.

More... »